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The search for major longevity genes in humans has so 
far had limited success and only the APOE and 
FOXO3A genes have been found to consistently 
associate with human longevity (e.g. [1-5]). Recently, 
however, a third longevity locus was proposed based on 
the results of a genome-wide association meta-analysis 
including 12,736 long-lived individuals ≥ 85 years and 
76,268 younger controls < 65 years of European descent 
[6]. In this study, the single nucleotide polymorphism 
(SNP) rs2149954 on chromosome 5q33.3 was found to 
associate with survival to beyond 90 years of age (OR = 
1.10, P = 1.74×10-8). This association has afterwards 
been confirmed in a genome-wide association study of 
exceptional longevity in Han Chinese centenarians (P = 
0.02) [7]. Investigation of  the  effect  of  rs2149954  on  
 
prospective survival in the meta-analysis showed a 
significant association with lower all-cause mortality 
(HR = 0.95, P = 0.003) as well [6]. Further investigation 
of cause-specific mortality in a sub-group analysis 
revealed that the lower mortality seen in rs2149954 
minor allele carriers was partly conferred by a 
decreased mortality risk for cardiovascular disease, 
primarily due to protection from stroke. However, a 
protective effect of the rs2149954 minor allele on 
mortality independent of cardiovascular disease was 
also found. 
 
Previous studies in middle-aged individuals have 
revealed a significant association between the 
rs2149954 minor allele and a decreased risk for 
coronary artery disease, and lower diastolic and systolic 
blood pressure [6, 8, 9]. Also, two SNPs on 



















cause mortality, thus suggesting  it as a third human  longevity  locus alongside APOE and FOXO3A. The 5q33.3
locus has previously been associated with blood pressure regulation and cardiovascular diseases in middle‐aged
individuals.  However,  part  of  the  influence  on  mortality  appears  to  be  independent  of  cardiovascular
phenotypes, and  the  role of  the 5q33.3  locus  in  longevity and  survival  is  therefore  still partly unknown. We
investigated the association between  the  longevity‐associated variant rs2149954 on chromosome 5q33.3 and
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chromosome 5q33.3 in high LD with rs2149954, 
rs9313772 and rs11953630, have been reported to be 
associated with blood pressure and hypertension [8, 10]. 
In individuals older than 75 years the association 
between rs2149954 and all-cause mortality was, 
however, not found to be influenced by blood pressure 
[6]. 
 
So, although there is an established connection between 
rs2149954 and different cardiovascular phenotypes, 
there also seems to be an effect of the variant in 
mechanisms other than those associated with 
cardiovascular disease and blood pressure regulation, at 
least in long-lived individuals. The role of the 5q33.3 
locus in survival and longevity is therefore still partly 
unknown. 
 
To further explore this, we investigated the influence of 
rs2149954 on age-related phenotypes previously shown 
to predict survival in the oldest-old [11, 12]: cognitive 
function (evaluated by a 5-item cognitive composite 
score and the Mini-Mental State Examination 
(MMSE)), physical function (evaluated by an activity of 
daily living (ADL) strength score, hand grip strength, 
gait speed, and chair stand), ADL disability, depression 
symptomatology, and self-rated health. In addition, self-
reported diseases related to cancer and cardiovascular 
disease, which are among the leading causes of death in 
Denmark, were explored. The apparent age-dependent 
pleiotropy in the role of the 5q33.3 locus was addressed 





Characteristics of the four study cohorts are 
summarized in Table 1, which also includes information 
on the rs2149954 minor allele frequency in each study 
cohort. The results of the  association  analyses  between  
 
rs2149954 and the self-reported diseases and age-
related phenotypes in the four study cohorts are shown 
in Table 2. 
 
The investigated SNP was found to be in Hardy-
Weinberg equilibrium in all study cohorts (P > 0.70, 
data not shown).  
 
The primary focus of this study was to investigate the 
association between rs2149954 and age-related 
phenotypes, including self-reported diseases, in long-
lived individuals. This was done in two study cohorts: 
long-lived individuals 1 (LLI-1) consisting of long-lived 
individuals from the 1905 Birth Cohort Study and long-
lived individuals 2 (LLI-2) consisting of long-lived 
individuals from the 1910 and 1915 Birth Cohort 
Studies. When applying a stringent Bonferroni 
correction, no significant associations were found. 
However, in the LLI-1study cohort we found nominally 
significant associations between the minor allele of 
rs2149954 and a decreased risk of heart attack and heart 
failure. Also, minor allele carriers were found to have an 
increased ADL strength score, indicating a better 
physical functioning. In contrast, no nominally signi-
ficant associations were found in the LLI-2 study cohort. 
 
To also address the previously suggested age-related 
pleiotropy in the effect of the 5q33.3 locus, we analyzed 
the association between rs2149954 and available age-
related phenotypes and self-reported diseases in middle-
aged and elderly individuals as well. In the middle-aged 
individuals we found a nominally significant association 
between the rs2149954 minor allele dose and a lower 
risk for hypertension. A similar association was also 
seen in the elderly individuals, where we additionally 
found indications of an association between rs2149954 
and a lower risk of cancer and increased physical 
performance represented by a higher ADL strength 
score and improved chair stand. 
 
Table 1. Characteristics of the four study cohorts.
 Middle-aged1 Elderly2 LLI-13 LLI-24 
N 700 677 1,588 1,271 
Mean age (years) 52.5 78.7 93.1 95.9 
Age range (years) 45.9 – 59.0 73.0 – 95.5 92.2 – 93.8 94.7 – 100.9 
N Women (%) 424 (60.6%) 448 (66.2%) 1,138 (71.7%) 928 (73.0%) 
Minor allele frequency, rs2149954 0.3336 0.3597 0.3523 0.3533 
1 Middle‐aged refers to individuals from the Study of Middle‐Aged Danish Twins (MADT). 2 Elderly refers to individuals from the 
Longitudinal Study of Aging Danish Twins (LSADT). 3LLI‐1: Long‐lived individuals 1. 4LLI‐2: Long‐lived individuals 2. 




In the present study we investigated the association 
between the longevity-related variant rs2149954 on 
chromosome 5q33.3 and age-related phenotypes, 
including selected self-reported diseases, in long-lived 
as well as in middle-aged and elderly individuals. 
 
In LLI-1 we found a nominally significant association 
between rs2149954 and an increased ADL strength 
score. Also, we saw a nominally  significant  association  
 
with a decreased risk of heart attack and heart failure. 
These results support the previously suggested role of 
rs2149954 and the 5q33.3 locus in cardiovascular health 
[6, 8-10], and additionally they suggest a role of 
rs2149954 in physical functioning. It could be 
speculated that the influence of rs2149954 on physical 
functioning could somehow be mediated by the effect of 
rs2149954 on cardiovascular health. However, when 
adjusting for heart attack or heart failure in the analysis 
of the ADL strength score, the association remains the 
same, which could imply partly independent effects. 
Table 2. Association between rs2149954 and the self‐reported diseases and age‐related phenotypes in the four study 
cohorts adopting an additive genetic model. 
 Middle-aged Elderly LLI-1 LLI-2 
Self-reported Disease N OR P N OR P N OR P N OR P 
Cancer 700 0.85 0.684 677 0.73 0.082 1,579 1.02 0.905 1,265 1.03 0.830 
Angina Pectoris 700 1.01 0.984 676 1.40 0.170 1,579 0.98 0.889 1,264 1.23 0.167 
Heart Attack 700 1.01 0.994 677 0.89 0.612 1,581 0.74 0.049 1,266 1.13 0.404 
Heart Failure NA NA NA 676 0.83 0.378 1,577 0.78 0.040 1,263 1.03 0.897 
Hypertension 700 0.65 0.020 676 0.69 0.013 1,567 0.97 0.779 1,261 0.94 0.492 
Irregular Heart Rhythm 698 0.83 0.446 677 0.99 0.968 1,580 0.98 0.841 1,264 1.01 0.917 
Other Heart Problems 700 0.79 0.691 675 1.34 0.252 1,579 0.96 0.789 1,259 0.97 0.801 
Stroke 700 2.03 0.163 677 0.67 0.180 1,580 0.91 0.440 1,270 1.01 0.946 
Age-related Phenotype N OR P N OR P N OR P N OR P 
ADL Disability NA NA NA NA NA NA 1,586 0.92 0.259 1,266 1.08 0.327 
ADL Strength NA NA NA 676 1.27 0.066 1,571 1.18 0.023 1,254 0.94 0.440 
Chair Stand NA NA NA NA NA NA 1,488 1.11 0.155 1,250 0.89 0.150 
Chair Stand, Timed* 682 1.02 0.827 421 0.78 0.087 NA NA NA NA NA NA 
Depression 700 1.11 0.315 656 0.87 0.213 1,492 0.96 0.564 1,253 0.94 0.381 
Gait Speed NA NA NA NA NA NA 1,314 1.04 0.617 1,041 1.05 0.616 
MMSE NA NA NA 657 0.96 0.701 1,522 1.04 0.598 1,246 0.96 0.627 
Self-rated Health 700 0.84 0.105 661 1.12 0.294 1,526 1.02 0.819 1,265 1.06 0.416 
Age-related Phenotype N β P N β P N β P N β P 
Cognitive Composite Score 700 0.07 0.693 659 -0.07 0.727 1,518 0.02 0.877 1,244 -0.17 0.252 
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The nominally significant findings in LLI-1 could not 
be replicated in LLI-2, which may indicate that the 
findings in LLI-1 are chance findings. The lack of 
consistency could, however, also be a consequence of 
the difference of 2.8 years in mean age (93.1 years in 
LLI-1 vs. 95.9 years in LLI-2), which makes the 
selection pressure substantially higher in LLI-2 [13, 14]. 
Also, a recent study showed that nonagenarians from 
the 1915 Birth Cohort Study, who make up the majority 
of LLI-2, performed significantly better on cognitive 
tests and activity of daily living activities compared to 
nonagenarians from the 1905 Birth Cohort Study, who 
make up LLI-1 [15]. This together with the age 
difference could potentially dilute the genetic effect in 
LLI-2.  
 
In the middle-aged and elderly individuals, we found a 
nominally significant association between the minor 
allele of rs2149954 and a lower risk of hypertension. 
This is supported by an analysis of the diastolic and 
systolic blood pressure measured in the middle-aged 
individuals at a later follow-up assessment (data not 
shown). Here we find that homozygous carriers of the 
rs2149954 minor allele have lower diastolic and systolic 
blood pressure, which is in line with the previously 
found association between rs2149954 and lower 
diastolic and systolic blood pressure in middle-aged 
individuals [6, 8].  
 
Overall, our results support a role of rs2149954 in 
cardiovascular health, and we confirm the previously 
found association between rs2149954 and a lower risk 
of hypertension in middle-aged as well as in elderly 
individuals. The 5q33.3 locus thus appears to play a 
persistent role in cardiovascular health throughout the 
entire age-span investigated here, although we see a 
shift with age from a role in hypertension to a role in 
heart attack and heart failure. This shift is supported by 
a number of studies indicating that while high blood 
pressure is disadvantageous in midlife it appears to be 
advantageous at higher ages where it is associated with 
better physical and cognitive health and lower all-cause 
mortality [16-19]. This reversal of risk has been 
suggested to take place around the age of 75 to 85 years 
[20] and it is thus consistent with the age-related 
attenuation that we see for the association between 
rs2149954 and hypertension.  
 
Our results also suggest a role for rs2149954 and the 
5q33.3 locus in physical functioning. In a recent study, 
lower blood pressure in midlife was found to associate 
with better physical functioning in old age [21], which 
supports our results of a role for rs2149954 in 
hypertension in the middle-aged and elderly individuals 
and a role in physical functioning in the long-lived 
individuals.  
In conclusion, our results point o a role of rs2149954 
and 5q33.3 in cardiovascular health and physical 
functioning. Additional, preferably longitudinal and 
functional studies are needed to further improve the 
understanding of the role of this locus in longevity and 






The individuals included in this study were middle-
aged, elderly and long-lived participants from five 
different surveys conducted at the University of 
Southern Denmark.  
 
The middle-aged individuals were drawn from the 
Study of Middle Aged Danish Twins (MADT). MADT 
was initiated in 1998 and includes 4,314 twins 
randomly chosen from the birth years 1931-1952 [22]. 
Surviving participants were revisited from 2008 to 
2011[23]. Here, we included 700 twins randomly 
selected among twins born in 1940 or later. Only one 
twin from each twin pair was included. 
 
The elderly individuals were drawn from the 
Longitudinal Study of Aging Danish Twins (LSADT). 
LSADT was initiated in 1995 and includes twins aged 
70 years and older. Follow-up assessments were 
conducted every second year through 2005 [24]. The 
677 twins included in the present study all participated 
in the 1997 assessment, where a total of 689 individuals 
provided a blood sample. Both twin pairs and singletons 
were included.  
 
The long-lived individuals were drawn from three 
population-based nationwide surveys: the Danish 1905 
Birth Cohort Study, the Danish 1910 Birth Cohort 
Study, and the Danish 1915 Birth Cohort Study 
(Rasmussen et al. 2016, submitted). Briefly, the Danish 
1905 Birth Cohort Study was initiated in 1998, when 
participants were 92–93 years of age [25]. Follow-up 
assessments of participating survivors were carried out 
in 2000, 2003, and 2005. At intake there were 3,600 
potential participants, of whom 2,262 agreed to take 
part in the survey. Among the 2,262 participants, 1,651 
provided a biological sample, and 1,588 of these are 
included here. The Danish 1910 and 1915 Birth Cohort 
Studies include all Danes born in 1910 and 1915, and 
were initiated in 2010, when participants were 100 and 
95 years of age, respectively [15]. In the 1910 Birth 
Cohort Study, a total of 400 individuals were invited to 
participate, which 273 individuals agreed to. Blood 
samples were retrieved from 176 individuals, of whom 
175 are included here. In the 1915 Birth Cohort Study, 
2,509 individuals were identified as eligible 
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participants, and 1,584 individuals chose to participate. 
Blood samples were provided by 1,105 individuals, and 
1,096 of these are included in this study.  
 
Written informed consents were obtained from all 
participants, and all surveys, including collection of 
blood and use of survey information, were approved by 





DNA was extracted from dried blood spot cards using 
either the DNA Mini or Micro Kits (Qiagen, Hilden, 
Germany) or the Extract-N-AmpTM Blood PCR Kit 
(Sigma-Aldrich, St. Louis, MO, USA), or from whole 
blood using a manual [26] or a semi-automatic 
(Autopure, Qiagen, Hilden, Germany) salting out 
method.  
 
Genotyping of rs2149954 was performed using a 
predesigned TaqMan® SNP Genotyping Assay (Life 





Data on the self-reported diseases and age-related 
phenotypes investigated in this study (see 
Supplementary Table 1) was collected as part of a 
comprehensive home-based interview focusing on 
health and lifestyle issues as well as objective 
assessments of cognitive and physical abilities.  
 
Status on self-reported diseases was assessed by asking: 
‘Did a doctor ever tell you that you have/had any of the 
following diseases?’ with the response categories ‘no’ 
or ‘has now or has had’. Cognitive function was 
assessed by the Mini-Mental State Examination 
(MMSE) and  a cognitive composite score, which 
evaluates verbal fluency, forward and backward digit 
span, and immediate and delayed recall [27]. The 
MMSE score ranges from 0 to 30 and was here divided 
into four groups: severe impairment (MMSE 0-17), 
mild impairment (MMSE 18-22), normal (MMSE 23-
27), and maximum (28-30). Physical function was 
assessed by an activity of daily living (ADL) strength 
score, chair stand, gait speed, and grip strength. The 
ADL strength score was calculated as the average of 11 
individual items related to the ability to walk, run, climb 
stairs, and carry weights.  Each item was scored from 1 
to 4 with ‘1 = could not do’, ‘2 = could do with 
difficulty or an aid’, ‘3 = could do with fatigue’, and ‘4 
= could do without fatigue’, and the average was 
subsequently categorized into three: ‘ADL strength < 
2’, ‘ADL strength 2-<3’, and ‘ADL strength ≥ 3’. For 
chair stand different measures were used in the middle-
aged and elderly individuals compared to the long-lived 
individuals. In MADT and LSADT, chair stand was 
measured as the time used (in seconds) to stand up from 
a chair five times in a row as quickly as possible and 
subsequently divided into quartiles. In the 1905, 1910, 
and 1915 Birth Cohort Studies, chair stand assessed the 
ability to stand up from a chair with the outcome 
categories ‘cannot’, ‘can, with use of arms’, and ‘can, 
without use of arms’. Gait speed was measured as a 
timed walk (in seconds) of a distance of 3 m and was 
here categorized into ‘cannot walk’, ‘speed ≤ 0.375 
m/s’, and ‘speed > 0.375 m/s’. Grip strength was mea-
sured using a handheld dynamometer (SMEDLEY’s 
dynamometer, Scandidact, Kvistgaard, Denmark) and 
the maximum of three measurements with the strongest 
hand was used. The ADL disability score was based on 
a modified version of the Katz ADL index [28] and was 
computed from 8 questions relating to the five items 
bathing, dressing, toileting, transfer, and feeding. Here, 
the score was categorized into ‘not disabled = could do 
all 5 items’, ‘moderately disabled = could do 3 or 4 
items’, or ‘disabled = could do maximum 2 items’. 
Depression symptomatology was assessed using an 
adaption of the depression section of the Cambridge 
Mental Disorders of the Elderly Examination [29]. 
Scores were grouped into four categories based on 
quartiles with higher scores reflecting a higher level of 
depression. Self-rated health was evaluated by asking: 
‘How do you consider your health in general?’ with the 
five response categories ‘very poor’, ‘poor’, 




All statistical analyses were performed using the 
statistical software Stata (Stata version 13.1; Stata 
Corporation, College Station, TX, USA). Applying an 
additive genetic model with dose of minor allele (T) 
coded 0, 1, and 2, the association between rs2149954 
and the self-reported diseases were assessed using 
logistic regression. Linear regression was used for the 
analysis of cognitive composite score and grip strength, 
and ordinal logistic regression was used for the analysis 
of ADL disability, ADL strength, chair stand, 
depression symptomatology, MMSE, and self-rated 
health. All analyses were adjusted for age at assessment 
and gender. In the analysis of LSADT, the within-pair 
dependency of twin pairs was taken into account by 
including the cluster option. 
 
Given the a priori hypothesis of association between 
rs2149954 and longevity, blood pressure, and other 
cardiovascular phenotypes, and the correlation between 
the investigated phenotypes and diseases, a Bonferroni-
corrected significance level of P ≤ 7.4× 10-4 (correcting 
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for 17 age-related phenotypes and self-reported diseases 
in four study cohorts) is likely too stringent, and 
uncorrected P-values are thus reported. 
 
Power calculations were performed in Quanto (version 
1.2.4, http://biostats.usc.edu/ Quanto.html) assuming an 
additive model, a rs2149954 minor allele frequency of 
0.33 and a significance level of 0.05. For the continuous 
age-related phenotypes, cognitive composite score and 
grip strength, the calculations showed that effect sizes 
of 0.11 of a standard deviation (SD) or greater 
(corresponding to β-coefficients > 0.38 for cognitive 
composite score and β-coefficients > 0.74 for grip 
strength) could be detected with a power of at least 
80%. For the self-reported diseases, the calculations 
showed that depending on disease prevalence odds 
ratios larger that 1.3-1.5 (or smaller than 0.67-0.77) 
could be detected with a power of at least 80%. These 
calculations are all based on LLI-1, which to some 
extend is our discovery cohort. For LLI-2, and the 
middle-aged and elderly individuals, the power to detect 
the above-mentioned effect sizes is, in most instances, 
slightly reduced due to smaller study cohort sizes and 
lower disease prevalence.     
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 Middle-aged1 Elderly2 LLI-13 LLI-24 
Self-reported Disease N No. individuals 
(%) 
N No. individuals 
(%) 
N No. individuals 
(%) 
N No. individuals 
(%) 
Cancer 
     No  














     No  














    No  














     No  














     No  













Irregular Heart Rhythm 
     No  













Other Heart Problems 
     No  














     No  













Age-related Phenotype N No. individuals 
(%) 
N No. individuals 
(%) 
N No. individuals 
(%) 
N No. individuals 
(%) 
ADL Disability 
     Not disabled 
     Moderately disabled 


















     < 2 
     2-<3 


















     Cannot 
     Can, with use of arms 


















Chair Stand, Timed* 
     1st quartile 
     2nd quartile 
     3rd quartile 



























     1st quartile 
     2nd quartile 
     3rd quartile 






















     Cannot walk 
     Speed ≤ 0.375 m/s 


















     Severe impairment (0-
17) 
     Mild impairment (18-
22) 
     Normal (23-27) 























     Very poor 
     Poor 
     Acceptable 
     Good 

























Age-related Phenotype N Mean (SE) N Mean (SE)  Mean (SE) N Mean (SE) 
Cognitive Composite 
Score 
700 5.61 (0.12) 659 0.98 (0.13) 1,518 0.21 (0.09) 1,244 0.47 (0.10) 
Grip Strength* 693 37.80 (0.47) 484 24.31 (0.39) 1,424 16.28 (0.17) 1,091 15.93 (0.20) 
1  Middle‐aged  refers  to  individuals  from  the  Study  of  Middle‐Aged  Danish  Twins  (MADT).  2  Elderly  refers  to  individuals  from  the 
Longitudinal Study of Aging Danish Twins (LSADT). 3LLI‐1: Long‐lived individuals 1. 4LLI‐2: Long‐lived individuals 2. *In the elderly individuals 
these phenotypes were collected as part of the 1999 assessment of LSADT instead of the 1997 assessment. NA: Phenotype not available. 
